Immunotherapy
Here below, you will find a list of all the latest content published on this website on the topic of Cancer Immunology and Immunotherapy. The content is published in chronological order. Find out more about our content categorisation.
-
« Previous
- 1
- 2
- ...
- 70
-
Next »
- Nivolumab, Nivolumab Plus Ipilimumab ‘Supported’ For Western Refractory Oesophagogastric Cancer Patients
- Baseline Corticosteroid Use May Diminish NSCLC Immunotherapy Efficacy
- Radiomic Signature Predicts Response To PD-1 Pathway Blockade
- Diverse Delayed Skin Reactions To PD-1 Inhibitor Therapy Revealed
- Overall Survival Remains ‘Gold Standard’ For PD-1 Inhibitor Trial Endpoints
- Active8 Shows No ITT Survival Benefit For Motolimod Use In Recurrent, Metastatic SCCHN
- Highlights of Posters at ESMO GI on colorectal cancer
- Keynote Lecture: Understanding relevant immune mechanisms in GI oncology
- Metastatic gastric cancer: Where are we with check-point inhibitors in gastric cancer?
- Management of melanoma with immunotherapy and targeted treatment
- Adjuvant MAGE-A3 Vaccine Fails To Improve Stage III Melanoma Disease-Free Survival
- Immune check point inhibitors: Immunologic background, indications and innovations
- ASCO 2018: Immune Checkpoint Inhibitor Updates Reported For Merkel Cell Carcinoma
- Perspectives from ASCO 2018: Early breast cancer, the PERSEPHONE study
- Perspectives from ASCO 2018: Immunotherapy research in oncogene driven NSCLC, The ImmunoTarget and early combination study
- Perspectives from ASCO 2018: Advances in Gastric and Oesophageal Cancers, the KEYNOTE-061 trial
- Perspectives from ASCO 2018: Tumour mutation burden, a novel biomarker
- Perspectives from ASCO 2018: Novelties in Head and Neck cancers
- Perspectives from ASCO 2018: Highlights in multiple myeloma, the A.R.R.O.W. and OPTIMISMM trials
- ESMO videos: Perspectives from ASCO 2018
- ASCO 2018: TOPACIO/KEYNOTE-162 Findings ‘Promising’ For Metastatic TNBC and Recurrent Ovarian Cancer
- ASCO 2018: IMpower131 Meets PFS Target for Atezolizumab With Carboplatin And Nab-Paclitaxel
- ASCO 2018: KEYNOTE-042 Findings Adds Support For Pembrolizumab Use In PD-L1 Expressing NSCLC Patients
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
- Perspectives from ASCO 2018: First-line immunotherapy in advanced NSCLC, the KEYNOTE-042 trial
-
« Previous
- 1
- 2
- ...
- 70
-
Next »